Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Remimazolam vs propofol for perioperative sedation and neurocognitive outcomes in elderly hip fracture surgery
ChiCTR2200067024Phase 4Not yet recruiting
- Sponsor
- Lishui People's Hospital
- Start
- Dec 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised trial of remimazolam in hip fracture, postoperative delirium (POD) and Postoperative neurocognitive disorder (PND) (2 arms), sponsored by Lishui People's Hospital. Primary endpoints: Postoperative delirium and Modified sedation/alertness score. Planned start Dec 2022; status: not yet recruiting.
02
Drugs
remimazolam
03
Conditions
hip fracturepostoperative delirium (POD)Postoperative neurocognitive disorder (PND)
Beyond the preview
Go deeper on ChiCTR2200067024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200067024.